血浆和肽素水平预测常染色体显性多囊肾病疾病进展及托伐普坦疗效
该事后分析纳入TEMPO 3:4试验中1280例ADPKD患者,基线血浆和肽素可预测安慰剂组3年肾脏增长和eGFR下降,但校正基线总肾脏体积后不再显著。托伐普坦组和肽素从基线至第3周升高(6.3 pmol/L vs 21.9 pmol/L),基线和肽素较高者及和肽素升高幅度较大者托伐普坦疗效更好。
要点
- 基线血浆和肽素可预测ADPKD患者3年肾脏增长和eGFR下降。
- 托伐普坦治疗3周内血浆和肽素从6.3升至21.9 pmol/L。
- 基线高和肽素及治疗后和肽素升高幅度大者托伐普坦疗效更佳。
核心结论
- 血浆和肽素有望作为预测ADPKD疾病结局和托伐普坦疗效的生物标志物。
研究设计与样本
- TEMPO 3:4试验的事后分析,纳入1280例18-50岁、估计肌酐清除率≥60 ml/min且总肾脏体积≥750 mL的ADPKD患者,基线血浆和肽素采用自动化免疫荧光法测定。
主要发现
- 安慰剂组基线和肽素预测3年肾脏增长和eGFR下降,调整性别、年龄和基线eGFR后仍独立相关,但额外调整基线总肾脏体积后不再有统计学显著性。
- 托伐普坦组和肽素从基线至第3周由6.3 pmol/L升至21.9 pmol/L。
- 托伐普坦组基线和肽素较高者肾脏增长率和eGFR下降的治疗效应更大。
- 托伐普坦组第3周和肽素较基线升高百分比更大者3年后肾脏增长和eGFR下降更少。
临床怎么用
- 在ADPKD患者中可考虑检测血浆和肽素以辅助预测疾病进展和托伐普坦治疗反应。
局限性
- 为TEMPO 3:4试验的事后分析。
- 基线和肽素预测疾病进展的关联在调整基线总肾脏体积后不再显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether plasma copeptin levels, a marker of plasma vasopressin, are associated with disease progression, and whether pre-treatment copeptin and treatment-induced change in copeptin are associated with tolvaptan treatment efficacy. This post hoc analysis included 1,280 TEMPO 3:4 participants (aged 18-50 years, estimated creatinine clearance ≥60 ml/min and total kidney volume ≥750 mL) who had plasma samples available at baseline for measurement of copeptin using an automated immunofluorescence assay. In placebo-treated subjects, baseline copeptin predicted kidney growth and eGFR decline over 3 years. These associations were independent of sex, age, and baseline eGFR, but were no longer statistically significant after additional adjustment for baseline total kidney volume. In tolvaptan-treated subjects, copeptin increased from baseline to week 3 (6.3 pmol/L versus 21.9 pmol/L, respectively). In tolvaptan-treated subjects with higher baseline copeptin levels, a larger treatment effect was noted with respect to kidney growth rate and eGFR decline. Tolvaptan-treated subjects with a larger percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years. Copeptin holds promise as a biomarker to predict outcome and tolvaptan treatment efficacy in ADPKD.
引用
- Gansevoort RT, van Gastel MDA, Chapman AB, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019. PMID: 30898339. doi:10.1016/j.kint.2018.11.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。